FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women

British Journal of Cancer

Volumn 115, Issue 5, 2016, Pages 579-587

  Luttmer, Roosmarijn ^a   De Strooper, Lise M A ^a   Dijkstra, Maaike G ^a   Berkhof, Johannes ^a   Snijders, Peter J F ^a   Steenbergen, Renske D M ^a   Van Kemenade, Folkert J ^b   Rozendaal, Lawrence ^a   Helmerhorst, Theo J M ^b   Verheijen, René H M ^c   Ter Harmsel, W Abraham ^d   Van Baal, W Marchien ^e   Graziosi, Peppino G C M ^f   Quint, Wim G V ^g   Spruijt, Johan W M ^a   Van Dijken, Dorenda K E ^h   Heideman, Daniëlle A M ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Roosevelt Clinic   (Netherlands)

^e Flevo Hospital   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g DDL DIAGNOSTIC LABORATORY   (Netherlands)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

DNA methylation; cervical intraepithelial neoplasia; cervicovaginal lavage; self sampling; qMSP

Indexed keywords

DNA; CYTOKINE; TAFA4 PROTEIN, HUMAN;

ADENOCARCINOMA IN SITU; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CERVICOVAGINAL SELF-SAMPLING DEVICE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; ENDOMETRIAL BRUSH; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN TISSUE; LAVAGE FLUID; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; MULTICENTER STUDY (TOPIC); PAPILLOMAVIRUS INFECTION; POST HOC ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; ALPHAPAPILLOMAVIRUS; BIOPSY; COMPARATIVE STUDY; GENETICS; ISOLATION AND PURIFICATION; PATHOLOGY; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ALPHAPAPILLOMAVIRUS; BIOPSY; CYTOKINES; DNA METHYLATION; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84978519625     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.200     Document Type: Article

References (42)

1. Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao F-H, Hillemanns P, Anttila A. (2014). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 15: 172-183
2. Benard VB, Watson M, Castle PE, Saraiya M. (2012). Cervical carcinoma rates among young females in the United States. Obstet Gynecol 120: 1117-1123
3. Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DAM, Massuger LFAG, Verhoef VMJ, Bulten J, Melchers WJG, Van Der Zee AGJ, Bekkers RLM, Wisman GBA. (2014). DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer 111: 1095-1101
4. Chang C-C, Huang R-L, Liao Y-P, Su P-H, Hsu Y-W, Wang H-C, Tien C-Y, Yu M-H, Lin Y-W, Lai H-C. (2015). Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. BMC Cancer 15: 418
5. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J. (2013). Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 208: 184.e1-e184.e11
6. De Strooper LMA, Meijer CJLM, Berkhof J, Hesselink AT, Snijders PJF, Steenbergen RDM, Heideman DAM. (2014). Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila) 7: 1251-1257
7. De Strooper LMA, Verhoef VMJ, Berkhof J, Hesselink AT, de Bruin HM, van Kemenade FJ, Bosgraaf RP, Bekkers RLM, Massuger LFAG, Melchers WJG, Steenbergen RDM, Snijders PJF, Meijer CJLM, Heideman DAM. (2016). Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage-and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol 141(2): 341-347
8. Dijkstra M, van Niekerk D, Rijkaart D, van Kemenade FJ, Heideman DAM, Snijders PJF, Meijer CJ, Berkhof J. (2014). Primary hrHPV DNA testing in Cervical Cancer screening: how to manage screen positive women? A POBASCAM Trial sub study. Cancer Epidemiol Biomarkers Prev 23: 55-63
9. Dillner J. (2013). Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 25: 11-16
10. Eijsink JJH, Lendvai Á , Deregowski V, Klip HG, Verpooten G, Dehaspe L, de Bock GH, Hollema H, van Criekinge W, Schuuring E, Van Der Zee AG, Wisman GB. (2012). A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 130: 1861-1869
11. Eijsink JJH, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, van Hemel BM, Voll M, Coelingh Bennink HJT, Schuuring E, Wisman GB, Van Der Zee AG. (2011). Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 120: 280-283
12. Garcia F, Barker B, Santos C, Brown EM, Nuño T, Giuliano A, Davis J. (2003). Cross-sectional study of patient-and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 102: 266-272
13. Hesselink AT, Heideman DAM, Steenbergen RDM, Coupé VMH, Overmeer RM, Rijkaart D, Berkhof J, Meijer CJLM, Snijders PJF. (2011). Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 17: 2459-2465
14. Hesselink AT, Heideman DAM, Steenbergen RDM, Gök M, van Kemenade FJ, Wilting SM, Berkhof J, Meijer CJLM, Snijders PJF. (2014). Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 135: 880-886
15. Huang T-H, Lai H-C, Liu H-W, Lin CJ, Wang K-H, Ding D-C, Chu T-Y. (2010). Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int J Gynecol Cancer 20: 513-519
16. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM. (2010). Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 19: 1585-1594
17. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. (1997). A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 35: 791-795
18. Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow S-N, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat M-C, Descamps D, Struyf F, Dubin GO, Rosillon D, Baril L. (2013). Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One 8: e79260
19. Landis JR, Koch GG. (1977). The measurement of observer agreement for categorical data. Biometrics 33: 159-174
20. Luttmer R, De Strooper LMA, Berkhof J, Snijders PJF, Dijkstra MG, Uijterwaal MH, Steenbergen RDM, Kemenade FJ, Van, Rozendaal L, Helmerhorst TJM, Verheijen RHM, Harmsel WA, Ter, Baal WM, Van, Heideman AM, Meijer CJLM. (2016). Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study). Int J Cancer 138: 992-1002
21. Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DAM, Snijders PJF. (2009). Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124: 516-520
22. Moriarty AT, Nayar R, Arnold T, Gearries L, Renshaw A, Thomas N, Souers R. (2014). The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med 138: 1182-1185
23. Nobbenhuis MAE, Helmerhorst TJM, van den Brule AJ, Rozendaal L, Jaspars LH, Voorhorst FJ, Verheijen RHM, Meijer CJLM. (2002). Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 55: 435-439
24. Ogilvie GS, Patrick DM, Schulzer M, Sellors JW, Petric M, Chambers K, White R, FitzGerald JM. (2005). Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 81: 207-212
25. Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJLM, Snijders PJF, Steenbergen RDM. (2009). Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 219: 327-336
26. Overmeer RM, Henken FE, Snijders PJF, Claassen-Kramer D, Berkhof J, Helmerhorst TJM, Heideman DAM, Wilting SM, Murakami Y, Ito A, Meijer CJLM, Steenbergen RDM. (2008). Association between dense CADM1 promoter methylation and reduced protein expression in highgrade CIN and cervical SCC. J Pathol 215: 388-397
27. Overmeer RM, Louwers JA, Meijer CJLM, van Kemenade FJ, Hesselink AT, Daalmeijer NF, Wilting SM, Heideman DAM, Verheijen RHM, Zaal A, van Baal WM, Berkhof J, Snijders PJF, Steenbergen RDM. (2011). Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J cancer 129: 2218-2225
28. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupé VMH, Hesselink AT, Rozendaal L, Heideman DAM, Verheijen RH, Bulk S, Verweij WM, Snijders PJF, Meijer CJLM. (2012). Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 130: 602-610
29. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJLM. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524-532
30. Saavedra KF, Brebi PS, Roa JC. (2012). Epigenetics alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenet 4: 13
31. Schmitt M, Bravo IG, Snijders PJF, Pawlita M, Waterboer T, Gissmann L. (2006). Bead-based multiplex genotyping of human papillomaviruses bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512
32. Snijders PJF, Steenbergen RDM, Heideman DAM, Meijer CJLM. (2006). HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 208: 152-164
33. Snijders PJF, Verhoef VMJ, Arbyn M, Ogilvie G, Minozzi S, Banzi R, van Kemenade FJ, Heideman DAM, Meijer CJLM. (2013). High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 132: 2223-2236
34. Steenbergen RDM, Kramer D, Braakhuis BJM, Stern PL, Verheijen RHM, Meijer CJLM, Snijders PJF. (2004). TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 96: 294-305
35. Steenbergen RDM, Ongenaert M, Snellenberg S, Trooskens G, Van Der Meide WF, Pandey D, Bloushtain-Qimron N, Polyak K, CJLM Meijer, Snijders PJF, Van Criekinge W. (2013). Methylation-specific digital karyotyping of HPV16E6E7 expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol 231: 53-62
36. Steenbergen RDM, Snijders PJF, Heideman DAM, Meijer CJLM. (2014). Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 14: 395-405
37. Tang N-S, Tang M-L, Chan ISF. (2003). On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 22: 1217-1233
38. Verhoef VMJ, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DAM, Hesselink AT, Bekkers RLM, Steenbergen RDM, Massuger LFAG, Melchers WJG, Bulten J, Overbeek LIH, Berkhof J, Snijders PJF, Meijer CJLM. (2014a). Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 15: 315-322
39. Verhoef VMJ, Heideman DAM, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, Bekkers RLM, Massuger LFAG, Steenbergen RDM, Snijders PJF, Berkhof J, Meijer CJLM. (2014b). Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol Oncol 135: 58-63
40. Wilting SM, van Boerdonk RAA, Henken FE, CJLM Meijer, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJF, Steenbergen RDM. (2010). Methylation-mediated silencing and tumour suppressive function of hsamiR-124 in cervical cancer. Mol Cancer 9: 167
41. Winer RL, Lee S-K, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. (2003). Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157: 218-226
42. Zorzi M, Del Mistro A, Farruggio A, de Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A. (2013). Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG 120: 1260-1267; discussion 1267-1268